MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 2, 2006--Geron Corporation (Nasdaq:GERN) today provided clarification with respect to license rights granted to third parties to develop cancer vaccines targeting telomerase.
MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 2, 2006--Geron Corporation (Nasdaq:GERN) today provided clarification with respect to license rights granted to third parties to develop cancer vaccines targeting telomerase.